Nearly half of patients taking certain drugs for Parkinson’s disease may eventually develop impulse control disorders such as compulsive eating, gambling or shopping, according to a new French study published in the journal Neurology.
Parkinson’s disease leads to a reduction in dopamine, a brain chemical that regulates movement. This is often treated with levodopa, a medication which converts to dopamine in the brain, or with dopamine agonists, which work by activating dopamine receptors.
The findings show that patients who are taking higher doses of these drugs and taking them for longer periods of time are at greater risk. The drugs pramipexole and ropinirole were associated with the highest risk of developing the disorders.
“Our study suggests that impulse control disorders are even more common than we thought in people who take dopamine agonists,” said study author Jean-Christophe Corvol, M.D., of the ICM Brain and Spine Institute, Sorbonne University in Paris, France. “These disorders can lead to serious financial, legal and social and psychological problems.”
For the study, researchers assessed 411 people who had been diagnosed with Parkinson’s disease for five years or less. They were followed for an average of about three years. The participants were asked in interviews about impulse control disorders such as compulsive shopping, eating, gambling or sexual behaviors.
About 87 percent of the patients had taken a dopamine agonist at least once. At the beginning of the study, 20 percent of the participants had an impulse control disorder, with 11 percent having compulsive or binge eating problems, 9 percent compulsive sexual behaviors, 5 percent compulsive shopping and 4 percent compulsive gambling. Six percent of the participants had more than one impulse control disorder.
Of the 306 participants who did not have impulse control disorders when the study began, 94 individuals developed a disorder during the study period, for an overall five-year cumulative incidence of 46 percent.
Among those who had never taken dopamine agonists, the five-year incidence was 12 percent, compared to 52 percent for those who had taken the drugs. The average annual incidence was 26 per 1,000 person-years in people who never took the drugs, compared to 119 per 1,000 person-years in those who had taken the drugs.
“These disorders can be challenging for neurologists to discover,” said Laura S. Boylan, M.D., of New York University in New York, NY, and a fellow of the American Academy of Neurology, who wrote an editorial accompanying the article.
“People might be ashamed to tell their doctor about their problems, they may think these issues are not related to their Parkinson’s disease, or they may not even consider the disorders a problem. Plus, as doctors’ time for meeting with each patient gets shorter and shorter, bringing up sensitive issues gets harder and harder.”
A total of 30 participants with impulse control disorders who stopped taking dopamine agonists were followed during the study. The disorders stopped over time, with half of the people no longer having issues after a year.
Researchers said that since the participants were relatively young (average age of 62) and younger people are more likely to be given dopamine agonists and to have impulse control disorders, it’s possible that the occurrence rate of these disorders could be overestimated.
Source: American Academy of Neurology